NIT-110 (Solid tumors)
What is the Purpose of this Study?
If you choose to join this study, you will:
- Receive the study drug (NT-17) alone or in combination with Pembrolizumab by IV
- Have physical exams, blood and urine tests
- Have imaging scans (CT and/or MRI)
- Have heart scans (ECG)
- Give tumor tissue
- Receive the study drug (NT-17) alone or in combination with Pembrolizumab by IV
- Have physical exams, blood and urine tests
- Have imaging scans (CT and/or MRI)
- Have heart scans (ECG)
- Give tumor tissue
What is the Condition Being Studied?
Relapsed/Refractory Advanced Solid Tumors
Who Can Participate in this Study?
Adults who are diagnosed with:
- Triple negative breast cancer; OR
- Small cell lung cancer; OR
- Ovarian cancer
For more information about who can join this study, please contact the study team at CCI-TrialReferrals@duke.edu or 919-681-6468.
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to find out if an experimental drug called NT-17 is a safe and effective treatment for your cancer.
Study Details
Full Title
An Open-label Phase 1b/2a Study of NT-I7 (efineptakin alfa) in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Advanced Solid Tumors
Principal Investigator
Christopher Hoimes
Instructor in the Department of Medicine
Contacts
Center for Cancer Immunotherapy DCI Clinical Research Team
Phone: +1 919-681-6468
Protocol Number
IRB:
PRO00105543
NCT:
NCT04332653
ClinicalTrials.gov
View on ClinicalTrials.gov